VXRT:OTCMKTS
Vaxart Inc
US$ ०.४३
arrow_downward
-०.०२%(-०.००००७५) 1D
अक्टोबर ९, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VXRT...
Open
US$ ०.४४
High
US$ ०.४५
Low
US$ ०.४३
Mkt. cap
१०.६६ करोड
Avg. vol.
२.६५ लाख
Volume
१.९८ लाख
P/E ratio
२.६६
52-wk high
US$ ०.८४
52-wk low
US$ ०.३०
EPS
US$ ०.१६
Beta
१.०५
Shares outstanding
२४.२८ करोड
No. of employees
६५
Open
US$ ०.४४
High
US$ ०.४५
Low
US$ ०.४३
Mkt. cap
१०.६६ करोड
Avg. vol.
२.६५ लाख
Volume
१.९८ लाख
P/E ratio
२.६६
52-wk high
US$ ०.८४
52-wk low
US$ ०.३०
EPS
US$ ०.१६
Beta
१.०५
Shares outstanding
२४.२८ करोड
No. of employees
६५
News stories
From web sources and news partners
MarketBeat
·
३३ मिनेट पहिले
First Trust Emerging Markets AlphaDEX Fund (NASDAQ:FEM) Stock Short Interest Report for September
The Motley Fool
·
४२ मिनेट पहिले
Prediction: This Brilliant ETF Will Crush the S&P 500 Over the Next 20 Years
CryptoRank
·
१ घण्टा पहिले
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Yahoo Finance
·
२ घण्टा पहिले
S&P 500 Earnings Expected to Rise 31% in Q3 as AI-Related Companies Lead Growth
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees६५
Foundedमार्च २००४
HeadquartersSouth San Francisco, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitevaxart.com